

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM3/19 - Tumour Markers

Dead line: 06.08.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability						N _{eva}	N _{suc}	S _{rel}	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL					
(180) CA 125																
Samples and groups	[kU/L]				12								12	10	83%	
Sample A		9,42	2,7	29	12							12	11	92%		
Other					12	0						12				
							4x 4/1, 3x 4/12, 1x 4/60, 2x 4/149, 2x 4/179									
Sample B		17,8	5,6	32	12							12	10	83%		
Other					12	0						12				
							4x 4/1, 3x 4/12, 1x 4/60, 2x 4/149, 2x 4/179									
(181) CA 15-3																
Samples and groups	[kU/L]				11							11	8	73%		
Sample A		13,1	3,4	26	11							11	9	82%		
Other					11	0						11				
							4x 4/1, 2x 4/12, 1x 4/60, 2x 4/149, 2x 4/179									
Sample B		23,7	9,3	39	11							11	8	73%		
Other					11	0						11				
							4x 4/1, 2x 4/12, 1x 4/60, 2x 4/149, 2x 4/179									
(182) CA 19-9																
Samples and groups	[kU/L]				13							13	9	69%		
Sample A		99,1	74	75	13							13	11	85%		
Other					13	0						13				
							4x 4/1, 4x 4/12, 1x 4/60, 2x 4/149, 2x 4/179									
Sample B		8,16	5,2	63	13							13	10	77%		
Other					13	0						13				
							4x 4/1, 4x 4/12, 1x 4/60, 2x 4/149, 2x 4/179									
(183) CA 72-4																
Samples and groups	[kU/L]				12							11	11	100%		
Sample A		1,96	0,25	13	12							11	11	100%		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		1,93	0,22	11	11	0	CVPG	2 0,035 ±0,6	1,4	2,6		11				
Other					1	0						0				
							1x 1/185									
Sample B		7,37	0,61	8,2	12							11	11	100%		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		7,29	0,54	7,4	11	0	CVPG	7,89 0,22 20%	6,31	9,47		11				
Other					1	0						0				
							1x 1/185									
(184) CYFRA 21-1																
Samples and groups	[µg/L]				10							10	6	60%		
Sample A		7,51	1,4	19	10							10	7	70%		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		7,92	0,91	12	7	0	CVPG	8,01 0,090 18%	6,56	9,46		7				
Other					3	0						3				
							3x 4/1									
Sample B		30,8	4,8	15	10							10	8	80%		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		31,0	4,0	13	7	0	CVPG	32,3 0,32 18%	26,4	38,2		7				
Other					3	0						3				
							3x 4/1									
(185) AFP																
Samples and groups	[µg/L]				12							12	10	83%		
Sample A		2,46	0,46	19	12							12	11	92%		
Other					12	0						12				
							2x 4/1, 4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179									
Sample B		6,55	1,1	17	12							12	10	83%		
Other					12	0						12				
							2x 4/1, 4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179									
(186) hCG																
Samples and groups	[U/L]				13							13	10	77%		
Sample A		625	58	9,4	13							13	12	92%		
Other					13	0						13				
							1x 4/1, 4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179, 2x 4/210									
Sample B		31,8	2,4	7,5	13							13	10	77%		
Other					13	0						13				
							1x 4/1, 4x 4/12, 2x 4/60, 2x 4/149, 2x 4/179, 2x 4/210									
(189) CEA																
Samples and groups	[µg/L]				13							13	11	85%		
Sample A		8,77	1,1	13	13							13	12	92%		
Other					13	0						13				
							4x 4/1, 4x 4/12, 1x 4/60, 2x 4/149, 2x 4/179									
Sample B		30,3	6,8	23	13							13	11	85%		

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TM3/19 - Tumour Markers

Dead line: 06.08.2019

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(189) CEA					13								13	11	85%
Samples and groups	[µg/L]														
Sample A		30,3	6,8	23	13								13	11	85%
Other					13	0							13		
							4x 4/1, 4x 4/12, 1x 4/60, 2x 4/149, 2x 4/179								
(191) PSA					11								10	9	90%
Samples and groups	[µg/L]														
Sample A		0,678	0,17	25	11								10	10	100%
Other					11	0							10		
							3x 4/1, 3x 4/12, 1x 4/60, 1x 4/149, 2x 4/179, 1x 4/195								
Sample B		0,222	0,079	35	11								10	9	90%
Other					11	0							10		
							3x 4/1, 3x 4/12, 1x 4/60, 1x 4/149, 2x 4/179, 1x 4/195								
(194) NSE					9								9	9	100%
Samples and groups	[µg/L]														
Sample A		26,7	2,2	8,2	9								9	9	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		26,1	3,4	13	8	0	CVPG	25,8	0,28	30%	18	33,6	8		
Other					1	0							1		
							1x 3/24								
Sample B		8,45	1,0	12	9								9	9	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		8,47	1,4	17	8	0	CVPG	8	0,11	30%	5,6	10,4	8		
Other					1	0							1		
							1x 3/24								
(195) SCCA					6								6	6	100%
Samples and groups	[µg/L]														
Sample A		0,970	0,55	57	6								6	6	100%
Other					6	0							6		
							1x 3/24, 3x 4/1, 2x 4/60								
Sample B		0,865	0,69	80	6								6	6	100%
Other					6	0							6		
							1x 3/24, 3x 4/1, 2x 4/60								
(198) free-PSA					8								8	7	88%
Samples and groups	[µg/L]														
Sample A		0,460	0,10	23	8								8	8	100%
Other					8	0							8		
							3x 4/1, 2x 4/12, 1x 4/149, 1x 4/179, 1x 4/195								
Sample B		0,095	0,022	23	8								8	7	88%
Other					8	0							8		
							3x 4/1, 2x 4/12, 1x 4/149, 1x 4/179, 1x 4/195								
(201) S-100					4								4	3	75%
Samples and groups	[µg/L]														
Sample A		0,037	0,025	67	4								4	3	75%
Other					4	0							4		
							4x 4/60								
Sample B		0,072	0,018	25	4								4	4	100%
Other					4	0							4		
							4x 4/60								
(206) Calcitonin					2								1	1	100%
Samples and groups	[ng/L]														
Sample A		2,75	0,25	9,1	2								1	1	100%
Other					2	0							1		
							1x 1/24, 1x 4/29								
Sample B		13,8	2,2	16	2								1	1	100%
Other					2	0							1		
							1x 1/24, 1x 4/29								
(207) Thyreoglobulin					2								2	2	100%
Samples and groups	[µg/L]														
Sample A		6,24	1,6	26	2								2	2	100%
Other					2	0							2		
							1x 3/24, 1x 4/29								
Sample B		97,3	14	14	2								2	2	100%
Other					2	0							2		
							1x 3/24, 1x 4/29								
(208) beta-2-microglobulin					9								6	6	100%
Samples and groups	[mg/L]														
Sample A		4,78	0,096	2,0	9								6	6	100%
Other					9	0							6		
							1x 1/36, 1x 6/58, 1x 6/75, 1x 6/91, 4x 6/149, 1x 6/177								
Sample B		1,55	0,082	5,3	9								6	6	100%
Other					9	0							6		
							1x 1/36, 1x 6/58, 1x 6/75, 1x 6/91, 4x 6/149, 1x 6/177								